Efficacy and safety of treating alopecia areata with ritlecitinib

Dr. Brett King, Associate Professor of Dermatology at Yale School of Medicine, presents the findings of his trial published in The Lancet on 13 April 2023:

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

Read the full paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00222-2/fulltext?dgcid=youtube_video_lancet

Visit The Lancet at https://www.thelancet.com/journals/lancet/home?dgcid=youtube_video_lancet
Find out more at https://www.thelancet.com/?dgcid=youtube_video_lancet_lancet

* * *
Continue this conversation on social! Follow us today at…
https://Twitter.com/TheLancet
https://facebook.com/TheLancetMedicalJournal
https://LinkedIn.com/company/the-lancet

Видео Efficacy and safety of treating alopecia areata with ritlecitinib канала The Lancet